Novo Nordisk Leverages Artificial Intelligence to Accelerate Drug Launches and Enhance India Operations

Novo Nordisk Aims to Revolutionize Drug Development with AI

Novo Nordisk, the Danish pharmaceutical giant, is making a bold push to accelerate the development and launch of new drugs using artificial intelligence (AI). According to John Dawber, managing director for global business services, the company hopes to reduce the time it takes to bring new medications to market by up to two-thirds, a significant improvement over the current timeline.

Historically, from the final patient visit to the first regulatory filing, the process has taken around 1.5 years. However, with the implementation of AI, Novo Nordisk is now able to shorten this timeframe by several months. The company is leveraging AI across various critical stages of the launch process, including regulatory document drafting, safety data analysis, and commercial analytics for both marketed and clinical trial drugs.

This strategic move reflects a broader industry shift, as pharmaceutical companies increasingly turn to AI to accelerate research, streamline processes, and reduce costs. Industry forecasts suggest that machine learning could halve early-stage development timelines within the next three to five years. Novo Nordisk, however, is targeting more aggressive gains, thanks to rapid advances in AI tools now widely deployed across its India operations.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

India Takes Centre Stage in Novo Nordisk's Global Operations

Novo Nordisk's Bengaluru centre is playing an increasingly pivotal role in the company's global drug launches, handling a growing share of preparatory work, including the recently launched oral obesity pill in the United States. According to Dawber, a significant proportion of work for any market launch is now executed out of India, with the Bengaluru centre's contributions leaving an indelible mark on global drug launches.

Activities ranging from clinical data analysis and regulatory submissions to commercial planning are now increasingly carried out from India. Despite the expanding scope of operations, Dawber expects the company to be conservative in its hiring amid a wider restructuring.

Hiring and Restructuring Plans

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Novo Nordisk's global business services unit is expected to end the year with approximately 4,000 employees. This figure is lower than the company's earlier target of 5,000 employees by 2025. Dawber acknowledged that the goal is now too ambitious and instead emphasized the importance of hiring the right people for the right roles as the company scales its AI-led operations.

Note: The table above highlights the development timeframe comparisons mentioned in the article.